Sign up Australia
Proactive Investors - Run By Investors For Investors

Immuron receives R&D tax refund

Immuron receives R&D tax refund

Immuron (ASX:IMC) has received $1,469,763 in a cash refund from a Research & Development programs during 2015 in the form of tax concessions.

The Incentive refund is a tax concession for Australian biotechnology companies to fund ongoing research and development pipelines and advance promising programs.

Immuron’s marketed product, Travelan, is for the prevention of travellers’ diarrhoea, while its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH.

The company focuses on commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases.

Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

View full IMC profile

Immuron Timeline

May 27 2016

Related Articles

Blood test
September 28 2016
The group has ambitions to strengthen its transatlantic focus through organic and strategic growth
September 20 2016
The absence of a discount suggests there is a healthy appetite for the equity.
February 14 2017
It has unveiled plans to raise as much as £12mln, which should transform the business.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.